Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Canadian Federal Court Refuses Permanent Injunction Against JAMP’s Simlandi® (adalimumab) for Infringement of AbbVie’s Humira® Patent

Dec 4, 2023

The Canadian Federal Court has refused AbbVie’s application for a permanent injunction against JAMP for exploitation of Simlandi® until the expiration of AbbVie’s Humira® patent no. 2,904,458.  Despite JAMP conceding it infringed the ‘458 patent, it successfully argued that the injunction should not be granted for public interest reasons.  It argued that: 

  • there was an alternative remedy available (a reasonably royalty paid by JAMP to AbbVie); 
  • Humira® would not benefit from additional sales if Simlandi® was removed from the market as Simlandi® patients would be switched to another biosimilar for which AbbVie is likely receiving a royalty;  
  • the removal of Simlandi® would deprive patients of the only 80 mg/0.8 mL formulation available in Canada; and 
  • if Simlandi® and Yuflyma® (Celltrion) are removed, all Simlandi® patients will have to switch to a biosimilar with a higher injection volume and possibly citrate, which could increase injection site pain for these patients and cause them harm. 

The Court also found that two of AbbVie’s Humira® dosing regimen patents (nos. 2,504,868 and 2,801,917)were invalid for obviousness.